AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24477299 — intervention group
Group type: EXPERIMENTAL
Intervention: beer
Number of subjects: 74
Study 22914465 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 40
Study 22914465 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 40
Study 20570264 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol gel (0.06%)
Number of subjects: 69
Study 20570264 — intervention group
Group type: COMPARATOR
Intervention: Oral tibolone (2.5 mg)
Number of subjects: 69
Study 18950294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left bundle branch block (LBBB)
Number of subjects: 310
Study 18950294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right bundle branch block (RBBB)
Number of subjects: 310
Study 18950294 — intervention group
Group type: COMPARATOR
Intervention: Patients without bundle branch block (no BBB)
Number of subjects: 310
Study 18950294 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bundle branch block (BBB)
Number of subjects: 310
Study 16162191 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality‐of‐Life Therapy (QOLT)
Number of subjects: 35
Study 16162191 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 35
Study 15569557 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 15569557 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 0
Study 15569557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 11076820 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) and vitamin B(12) (1 mg) daily (n=59)
Number of subjects: 89
Study 11076820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 89
Study 8805892 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 1 ml + GTN 2 mg
Number of subjects: 0
Study 8805892 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA 2 ml + GTN 2 mg
Number of subjects: 0
Study 8805892 — intervention group
Group type: COMPARATOR
Intervention: EMLA 2 ml only
Number of subjects: 0
Study 1634449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (20 mg twice daily orally)
Number of subjects: 13
Study 1634449 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium chromoglycate
Number of subjects: 13
Study 1634449 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 13
Study 6236436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly ipratropium bromide (160 micrograms)
Number of subjects: 14
Study 6236436 — intervention group
Group type: COMPARATOR
Intervention: Nightly salbutamol (200 micrograms)
Number of subjects: 14
Study 6236436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly salbutamol plus ipratropium bromide
Number of subjects: 14
Study 31060367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure release technique for 60 seconds (T60s)
Number of subjects: 60
Study 31060367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure release technique for 90 seconds (T90s)
Number of subjects: 60
Study 31060367 — intervention group
Group type: COMPARATOR
Intervention: Pressure release technique for 30 seconds (T30s)
Number of subjects: 60
Study 27913796 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted intention monitoring (AIM)
Number of subjects: 74
Study 27480182 — intervention group
Group type: COMPARATOR
Intervention: MICT (30 min at 60-70% HRpeak, five times/week)
Number of subjects: 66
Study 27480182 — intervention group
Group type: EXPERIMENTAL
Intervention: 4HIIT (4×4 min bouts at 85-95% HRpeak, three times/week)
Number of subjects: 66
Study 27480182 — intervention group
Group type: EXPERIMENTAL
Intervention: 1HIIT (1×4 min bout at 85-95% HRpeak, three times/week)
Number of subjects: 66
Study 25804039 — intervention group
Group type: EXPERIMENTAL
Intervention: ET 90 mg four days or more a week
Number of subjects: 40
Study 25804039 — intervention group
Group type: COMPARATOR
Intervention: ET 90 mg 3 days or less a week
Number of subjects: 40
Study 22784436 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (n=200)
Number of subjects: 320
Study 22784436 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=120)
Number of subjects: 320
Study 22784436 — intervention group
Group type: COMPARATOR
Intervention: Implementation strategy
Number of subjects: 320
Study 19403441 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized representational intervention to improve symptom management (IRIS)
Number of subjects: 82
Study 19403441 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 82
Study 19403441 — intervention group
Group type: COMPARATOR
Intervention: Delayed IRIS (wait list) control
Number of subjects: 82
Study 19403441 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS by telephone
Number of subjects: 82
Study 17705753 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (longer stents with proximal end in the upper calix and distal end crossing the midline of the bladder)
Number of subjects: 120
Study 17705753 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (proper stent length with proximal end in the pelvis and lower end just beyond the vesicoureteral junction)
Number of subjects: 120
Study 17705753 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 120
Study 17705753 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 120
Study 15377968 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice group (serial administration of BESS)
Number of subjects: 50
Study 15377968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no serial administration of BESS)
Number of subjects: 50
Study 11565240 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week individual self-management and coping skills training program
Number of subjects: 40
Study 11565240 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study 9478251 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal inguinal hernioplasty (TAPP)
Number of subjects: 108
Study 9478251 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein technique
Number of subjects: 108
Study 8176571 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feedings while LUACs were in place
Number of subjects: 29
Study 8176571 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feedings (24 hours after removal of LUACs)
Number of subjects: 29
Study 2980956 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy (mean duration 357 days)
Number of subjects: 167
Study 2980956 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirin NSAID therapy (mean duration 67 days)
Number of subjects: 167
Study 29397351 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated multidisciplinary diabetes team care
Number of subjects: 53
Study 28826290 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage surgical procedure (Group I)
Number of subjects: 40
Study 28826290 — intervention group
Group type: COMPARATOR
Intervention: Two-stage surgical procedure (Group II)
Number of subjects: 40
Study 28826290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26513240 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention
Number of subjects: 60
Study 26513240 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Intervention
Number of subjects: 60
Study 25271499 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused rehabilitation
Number of subjects: 405
Study 25271499 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (comprehensive or brief multidisciplinary intervention)
Number of subjects: 405
Study 25271499 — intervention group
Group type: COMPARATOR
Intervention: Work-focused rehabilitation vs Control intervention
Number of subjects: 405
Study 22629163 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery (single-lobe/lesionectomy or multilobe resection plus multiple subpial transection and/or callosotomy)
Number of subjects: 18
Study 22629163 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery
Number of subjects: 18
Study 19648982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (high compression)
Number of subjects: 181
Study 19648982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (dressing selection)
Number of subjects: 181
Study 19648982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (pentoxifylline)
Number of subjects: 181
Study 19648982 — intervention group
Group type: COMPARATOR
Intervention: Usual care (compression after healing)
Number of subjects: 181
Study 17298716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal capsules of 200 mg of micronized progesterone (Utrogestan), 3 times daily
Number of subjects: 244
Study 17298716 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone in gel (Crinone 8%), once daily
Number of subjects: 244
Study 15471654 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in palliative care
Number of subjects: 0
Study 15471654 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in palliative care
Number of subjects: 0
Study 11350327 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane through the agent‐saving device
Number of subjects: 16
Study 11350327 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane through the vaporiser
Number of subjects: 16
Study 11350327 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 9542476 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-761 (50 to 200 mg/day)
Number of subjects: 50
Study 9542476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8993088 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER (10‐60 mg/day)
Number of subjects: 123
Study 8993088 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (50‐300 mg/day)
Number of subjects: 123
Study 8993088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 8993088 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone ER
Number of subjects: 123
Study 8993088 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 2400306 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPL with saline solution
Number of subjects: 87
Study 2400306 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPL with saline solution and 2 g of chloramphenicol succinate
Number of subjects: 87
Study 2400306 — intervention group
Group type: COMPARATOR
Intervention: No IOPL
Number of subjects: 87
Study 6103212 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential stapling gun
Number of subjects: 30
Study 6103212 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand suturing technique
Number of subjects: 30
Study 31742903 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise (E2)
Number of subjects: 90
Study 31742903 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercise (E1)
Number of subjects: 90
Study 31742903 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 90
Study 31385489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy in addition to transcutaneous electrical nerve stimulation (TENS) and hot pack (HP) therapy
Number of subjects: 0
Study 31385489 — intervention group
Group type: COMPARATOR
Intervention: Sham magnetic field (without current flow) in addition to TENS and HP therapy
Number of subjects: 0
Study 31385489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 0
Study 31385489 — intervention group
Group type: COMPARATOR
Intervention: Sham magnetic field (without current flow)
Number of subjects: 0
Study 28564564 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 910
Study 28564564 — intervention group
Group type: COMPARATOR
Intervention: Control (no capecitabine)
Number of subjects: 910
Study 25582795 — intervention group
Group type: EXPERIMENTAL
Intervention: Full participation group (treatment) in the extension programme
Number of subjects: 0
Study 25582795 — intervention group
Group type: COMPARATOR
Intervention: Actively monitored control group
Number of subjects: 0
Study 25582795 — intervention group
Group type: COMPARATOR
Intervention: Passively monitored control group
Number of subjects: 0
Study 24838550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal jugular cannulation (group U, n=50)
Number of subjects: 100
Study 24838550 — intervention group
Group type: COMPARATOR
Intervention: Anatomic landmark guided internal jugular cannulation (group A, n=50)
Number of subjects: 100
Study 24838550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 22833205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 395
Study 21629152 — intervention group
Group type: EXPERIMENTAL
Intervention: Video asthma education materials
Number of subjects: 129
Study 21629152 — intervention group
Group type: COMPARATOR
Intervention: Written asthma education materials
Number of subjects: 129
Study 19054928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f) 50/50 extract
Number of subjects: 59
Study 19054928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17479860 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 114
Study 17479860 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 114
Study 17479860 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 114
Study 12953328 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intrauterine insemination (SIUI)
Number of subjects: 90
Study 12953328 — intervention group
Group type: EXPERIMENTAL
Intervention: Double intrauterine insemination (DIUI)
Number of subjects: 90
Study 12953328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 90
Study 10845014 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop haptic silicone intraocular lenses
Number of subjects: 48
Study 10845014 — intervention group
Group type: COMPARATOR
Intervention: Plate haptic silicone intraocular lenses
Number of subjects: 48
Study 9732884 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg)
Number of subjects: 123
Study 9732884 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.007 mg/kg)
Number of subjects: 123
Study 9732884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 9732884 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (after crossover from placebo)
Number of subjects: 123
Study 9732884 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (Propafenone vs Digoxin)
Number of subjects: 123
Study 7995864 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT1
Number of subjects: 37
Study 7995864 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT2
Number of subjects: 37
Study 7995864 — intervention group
Group type: EXPERIMENTAL
Intervention: OX3
Number of subjects: 37
Study 3338379 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group meetings with NIDDM patients, consisting of three weekly lessons presented by a physician, nurse, and dietitian once every 4 months.
Number of subjects: 51
Study 3338379 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group meetings with NIDDM patients
Number of subjects: 51
Study 3338379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 51
Study 29595122 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (1.5 mg/d) administered subcutaneously
Number of subjects: 30
Study 29145831 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week online COPD rehabilitation program (CORe) - group supervised resistance and endurance training and patient education, 60 min, three times/week at home via online screen.
Number of subjects: 134
Study 29145831 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient COPD rehabilitation (CCRe) - group based supervised resistance and endurance training and patient education, 90 min, two times/week for 10 weeks or 12 weeks in groups at the local hospital.
Number of subjects: 134
Study 29145831 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week online COPD rehabilitation program (CORe)
Number of subjects: 134
Study 29145831 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient COPD rehabilitation (CCRe)
Number of subjects: 134
Study 25082982 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 246
Study 25082982 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail intervention
Number of subjects: 246
Study 25082982 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 246
Study 23231379 — intervention group
Group type: EXPERIMENTAL
Intervention: TM81 (6 g, three times daily for 12 weeks)
Number of subjects: 480
Study 23231379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g, three times daily for 12 weeks)
Number of subjects: 480
Study 21572372 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 47
Study 17475527 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (12 microg formoterol twice daily)
Number of subjects: 392
Study 17475527 — intervention group
Group type: COMPARATOR
Intervention: Aerolizer (12 microg formoterol twice daily)
Number of subjects: 392
Study 17475527 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer
Number of subjects: 392
Study 17475527 — intervention group
Group type: COMPARATOR
Intervention: Aerolizer
Number of subjects: 392
Study 17475527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 392
Study 17068305 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA treatment
Number of subjects: 2184
Study 17068305 — intervention group
Group type: COMPARATOR
Intervention: No rt-PA treatment
Number of subjects: 2184
Study 12687029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg daily propelled by HFA 134a
Number of subjects: 315
Study 12687029 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg daily propelled by CFCs 11 and 12
Number of subjects: 315
Study 12687029 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FP HFA 134a vs FP CFC
Number of subjects: 315
Study 11145492 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg daily
Number of subjects: 191
Study 11145492 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg daily
Number of subjects: 191
Study 11145492 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg daily
Number of subjects: 191
Study 11145492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 9368159 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-suture phacoemulsification
Number of subjects: 131
Study 9368159 — intervention group
Group type: EXPERIMENTAL
Intervention: One-suture phacoemulsification
Number of subjects: 131
Study 9368159 — intervention group
Group type: EXPERIMENTAL
Intervention: No-suture phacoemulsification
Number of subjects: 131
Study 9368159 — intervention group
Group type: COMPARATOR
Intervention: Sutureless phacoemulsification
Number of subjects: 131
Study 8015532 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 14
Study 8015532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2895628 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 mg/kg/day) + Plasma exchange
Number of subjects: 72
Study 2895628 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 mg/kg/day) + Plasma exchange + Cyclophosphamide (2 mg/kg/day for 1 year)
Number of subjects: 72
Study 30511149 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families Oregon (HFO) program
Number of subjects: 1438
Study 30511149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1438
Study 31222572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajust®
Number of subjects: 205
Study 31222572 — intervention group
Group type: COMPARATOR
Intervention: SMUS
Number of subjects: 205
Study 28351523 — intervention group
Group type: EXPERIMENTAL
Intervention: Original delineation
Number of subjects: 88
Study 28351523 — intervention group
Group type: COMPARATOR
Intervention: Gold standard (GS) delineation
Number of subjects: 88
Study 25456979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous theta-burst stimulation (pcTBS)
Number of subjects: 14
Study 25456979 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 14
Study 25456979 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 14
Study 24626980 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intervention with the mother (6 weeks)
Number of subjects: 21
Study 24626980 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intervention with educational software program (6 weeks)
Number of subjects: 21
Study 21355966 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-guaranteed pressure support (PSV-VTG)
Number of subjects: 28
Study 21355966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV)
Number of subjects: 28
Study 21355966 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted pressure controlled ventilation (APCV)
Number of subjects: 28
Study 21355966 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-guaranteed pressure support (PSV-VTG) and Pressure support ventilation (PSV)
Number of subjects: 28
Study 18292433 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 16
Study 18292433 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16
Study 18292433 — intervention group
Group type: COMPARATOR
Intervention: Verbal command
Number of subjects: 16
Study 16537575 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 3648